Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

A 20-year-old male experienced mental fog after resuming topical minoxidil for hair loss, questioning if it's due to interactions with antidepressants. Suggestions included trying a lower concentration of minoxidil or alternatives like copper peptides.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses concerns about getting a hair transplant with the potential release of a new treatment, PP405, which may regrow dormant hair follicles. The user is currently using Minoxidil, Derma, and Keto but is waiting to start finasteride or dutasteride.

A 20-year-old is concerned about hair thinning despite using finasteride and minoxidil for over a year. They are advised to manage anxiety, consider therapy, and possibly reassess their treatment plan, while others suggest checking thyroid levels and considering alternative treatments like dutasteride.

RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Hair loss can significantly impact confidence and mental health, but there are various treatments like finasteride, minoxidil, dutasteride, hair systems, and lifestyle changes that may help. It's important to maintain hope and focus on what can be controlled, as different solutions work for different people.

Staying positive and managing stress may slow hair loss, but treatments like finasteride, minoxidil, and dutasteride are essential for managing male pattern baldness. Stress can accelerate hair loss, but genetics play a significant role, and early treatment is crucial.

A person is struggling with hair loss despite using finasteride and minoxidil, considering dutasteride and magnesium supplements. They are advised to be patient, consider a hair transplant, and check for thyroid issues.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Caffeine might raise stress hormones, potentially worsening hair loss. Telogen effluvium is often misattributed to minor stressors rather than significant life events.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

Hair loss has severely impacted the mental health and confidence of young individuals, making them feel unrecognizable and isolated. Treatments like oral minoxidil, finasteride, and PRP sessions are being considered, but results and side effects vary, leaving many feeling hopeless.

An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.

Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

A woman experiencing hair loss for over three years was diagnosed with female pattern hair loss and later with telogen effluvium, leading to a temporary stop of spironolactone treatment. She questions the diagnosis and treatment as her hair continues to worsen despite being advised to wait it out.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Finasteride made the original poster feel better, with increased energy and less frequent urination, but they were advised to see a doctor due to potential prostate issues. Some users reported positive effects like increased libido and reduced anxiety, while others experienced negative side effects like brain fog and erectile dysfunction.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

Some users attribute erectile dysfunction (ED) to finasteride, but others suggest porn use or other factors might contribute. There are mixed opinions on finasteride's side effects, with some experiencing mental health issues and others defending its use for hair loss.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.